> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rezolute's Experimental Drug Clears Nine-Responder Trial Threshold With 13 Responders In Preliminary Results
- URL: https://www.bullished.co/rezolutes-experimental-drug-clears-nine-responder-trial-threshold-with-13-responders-in-c7018761/
- Published: 2026-11-13T11:36:09.000Z
- Updated: 2026-11-13T11:36:09.000Z
- Description: Twelve participants stopped intravenous glucose entirely; Rezolute expects the completed-study analysis by mid-December 2026.
- Author: Matteo Parrino
- Tags: SEC Filings, RZLT, Industry: Healthcare

[Rezolute](https://www.bullished.co/tag/rzlt/), which develops treatments for dangerously low blood sugar, reported Friday that its experimental drug ersodetug produced [13 responders](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926126502/tm2627558d10%5F8k.htm?ref=bullished.co) in a tumor-related trial, exceeding the nine needed to meet its main goal. The results announced in an SEC filing are preliminary, with the completed-study statistical analysis still ahead.

## Twelve Patients Stopped Glucose Infusions

Among the 16 participants, 12 stopped receiving intravenous glucose entirely. To count as a responder, a patient needed to reduce glucose infusion requirements by at least 50% from their starting level, according to the company's release.

The study's [nine-responder threshold](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926126502/tm2627558d10%5Fex99-1.htm?ref=bullished.co) is designed to establish statistical significance. It requires the lower end of the 95% confidence interval for the response rate to exceed 30%.

The preliminary assessment took place on November 5\. Three participants remain in the main treatment period, including two who have yet to qualify as responders.

One participant left the study early, chose home hospice care and died a week later from cancer progression, as previously reported. The study counts that participant as a non-responder.

## An Eight-Week Test In Tumor Patients

All participants receive ersodetug and know which treatment they are getting. Patients requiring continuous glucose infusions receive a weekly dose of 9 milligrams per kilogram for eight weeks alongside standard care, then may continue treatment less frequently in an extension.

Enrollment includes 12 people with malignant insulin-secreting tumors called insulinomas and four with non-islet cell tumors. Both tumor types can overactivate insulin receptors and cause low blood sugar. Rezolute reported no safety findings attributed to ersodetug during the main treatment period or extension.

Researchers also assess how quickly patients stop infusions, leave hospital when applicable, and experience low blood sugar outside hospital, as well as patient-reported quality of life.

## Approval Plans Extend Beyond Tumor Disease

Ersodetug is an intravenous antibody designed to reduce excessive insulin-receptor activity. Rezolute is also studying it for congenital hyperinsulinism, which affects children, and supplies it through an expanded-access program for patients unable to join a clinical trial. The company has no approved products.

Rezolute spent about $53.8 million on research and development in the fiscal year ended June 30, 2026\. Its development effort covers persistent hypoglycemia linked to excess insulin activity.

Founder and CEO Nevan Charles Elam said the tumor results resembled outcomes seen through expanded access over the last few years. He said, "we look forward to [discussions with FDA](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926126502/tm2627558d10%5Fex99-1.htm?ref=bullished.co) in the first quarter of 2027."

The FDA has recommended an approval application for congenital hyperinsulinism following a preparatory meeting. Rezolute cautioned that the agency may find the evidence insufficient to establish meaningful clinical benefit or support approval. Ersodetug remains investigational.

Rezolute expects completed-study results, including the statistical analysis of the main efficacy measure, by mid-December 2026.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rezolute, Inc. (RZLT)](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926126502/tm2627558d10%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2627558d10\_ex99-1.htm — Rezolute, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926126502/tm2627558d10%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Rezolute Announces Positive Results from the Phase 3 upLIFT](https://www.globenewswire.com/news-release/2026/11/13/3402451/0/en/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism.html?ref=bullished.co) — globenewswire.com

### More on Rezolute

- [Rezolute Has $90.0 Million In Cash And Investments As Drug Results Approach](https://www.bullished.co/rezolute-has-90-0-million-in-cash-and-investments-as-drug-results-approach-4d39640d/)
- [Rezolute Sizes Tumor Hyperinsulinism At $4-5 Billion, With Patients Needing Triple The Vials](https://www.bullished.co/rezolute-sizes-tumor-hyperinsulinism-at-4-5-billion-with-patients-needing-triple-the-vials-c8adbb53/)
- [Jennison Associates Takes A 5.5% Passive Stake In Rezolute, Holding 5.3 Million Shares](https://www.bullished.co/jennison-associates-takes-a-5-5-passive-stake-in-rezolute-holding-5-3-million-shares-2ac28d6a/)

[All Rezolute (RZLT) coverage →](https://www.bullished.co/tag/rzlt/)